HKSE · 1652.HK
Fusen Pharmaceutical Company Limited
HK$1.03+HK$0.03 (+3.0%)
Fusen Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
Loading market information…
HKSE · 2325.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 07:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Yunkang Group Limited’s quoted price sits in the lower half of its reported 52-week range, 50.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Yunkang Group Limited’s forward annual dividend is HK$0.02 per share, paid annual. The forward yield is 3.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Yunkang Group Limited’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Yunkang Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical institution alliances, which encompass assisting with the setup and enhancement of diagnostic centers, developing standard operating procedures for testing, delivering expert diagnostic consultations and staff training, sourcing necessary equipment, implementing smart Internet of Things technology, and providing logistics support. For diagnostic outsourcing, Yunkang Group conducts diverse tests, including pathology examinations; infectious disease diagnostics for conditions such as hepatitis B, tuberculosis, human papillomavirus, Epstein-Barr virus, rabies, and respiratory pathogens (via nucleic acid testing); genetic and reproductive health screenings; and routine diagnostic assessments for chronic ailments like kidney, blood, autoimmune, and endocrine metabolic diseases. Furthermore, the company caters to financial institutions and insurance firms by offering personalized diagnostic testing, medical report interpretation, and hospital referral services. Yunkang Group's capabilities also extend to information technology, medical logistics, procurement of medical equipment, healthcare technology development, and various project investments. These services are delivered through its network of independent clinical laboratories and integrated on-site diagnostic facilities.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
HK$1.03+HK$0.03 (+3.0%)
Fusen Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
HK$5.49-HK$0.01 (-0.09%)
Charmacy Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
HK$0.63-HK$0.02 (-2.34%)
Zhongzhi Pharmaceutical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.22% below the high.
HK$0.71+HK$0.03 (+3.65%)
Vincent Medical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 34.86% below the high.
HK$0.47-HK$0.02 (-4.08%)
China Biotech Services Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 54.81% below the high.
HK$1.39+HK$0.01 (+0.72%)
Suzhou Basecare Medical Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
HK$0.51-HK$0.02 (-3.81%)
Austar Lifesciences Limited’s quoted price sits in the lower half of its reported 52-week range, 60.24% below the high.
HK$0.40HK$0.00 (0.0%)
ClouDr Group Limited’s quoted price sits in the lower half of its reported 52-week range, 68.75% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
